DOI: 10.25881/BPNMSC.2020.15.42.004

Authors

Bocharov A.V.1, Sidorov D.V.1, Popov L.V.2

1 Kostroma Regional Clinical Hospital named after Korolev E.I., Kostroma

2 Pirogov National Medical and Surgical Center, Moscow

Abstract

Objective: compare the frequency and severity of bleeding thrombolytic drugs 2 (alteplase) and 3 generations (recombinant prourokinase) in patients with acute coronary syndrome with St segment elevation and the appointment of ticagrelor no later than 3 hours after the end of fibrinolysis.

Material and methods: The study included 101 patients: the alteplase group (n = 71) — actilize was used as a thrombolytic drug, and the prourokinase group (n = 30) — purolase was used.a comparison of the groups of alteplase (n = 71) and recombinant prourokinase (n = 30) in patients with acute coronary syndrome with St segment elevation and ticagrelor administration no later than 3 hours after the end of fibrigolysis was performed. The follow-up period for patients was 30 days after thrombolysis. The primary endpoint was bleeding of any localization and severity. The severity of hemorrhagic complications was assessed using TIMI and BARC scales.

Results: in the compared groups, there were no cases of fatal and intracranial bleeding; in the alteplase and purolase groups, minor bleeding was recorded 5 (7%) and 2 (6.7%), respectively, moderate bleeding — 2 (2.8%) and 0, respectively, and large bleeding — 1 (1.4%) and 0, respectively. There were no significant differences in the frequency and severity of bleeding between the groups of alteplase and prourokinase, namely: the frequency of bleeding (OR = 1.78; 95% CI = 0.35÷8.91; p = 0.73), the frequency of “heavy” bleeding (p = 0.66) and the frequency of “light” bleeding (OR = 1.53; 95% CI = 0.3÷7.84; p = 0.9).

Conclusion: there are no significant differences in the criteria for hemorrhagic safety between groups of patients with acute St-segment elevation coronary syndrome and early administration of ticagrelor after thrombolytic therapy with alteplase or recombinant prourokinase.

Keywords: ticagrelor, thrombolysis, acute coronary syndrome, alteplase, prourokinase.

References

1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119-117. Doi: 10.1093/eurheartj/ehx393.

2. Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N. Engl. J. Med. 2013;368:1379–1387. Doi: 10.1056/NEJMoa1301092.

3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009;361:1045–57. Doi: 10.1056/NEJMoa0904327.

4. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in patients with STEMI: randomized placebo-controlled trial. Lancet. 2005;366(9497):1607–1621. Doi: 10.1016/S0140-6736(05)67660-X.

5. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med.2005;352:1179–1189. Doi: 10.1056/NEJMoa050522.

6. Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the TicagRElor in pAtients with ST elevation myocardial infarction treated with Thrombolysis (TREAT) trial. Am. Heart J. 2018;202:89–96. Doi: 10.1016/ j.ahj.2018.02.17.

7. Rao SV, Pratt C, Berk A, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorragic manifestations and changes in plasma fibrinogen system and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. JACC. 1988;11(1):1–11. Doi: 10.1016/0735-1097(88)90158-1.

8. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials. A consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–2747. Doi: 10.1161/CIRCULATIONAHA.110.009449.

9. Berwanger O, Lopes RD, Moia DDF, et al. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis. TREAT Trial. JACC. 2019;73(22):2819–2828. Doi: 10.1016/j.jacc.2019.03.011.

For citation

Bocharov A.V., Sidorov D.V., Popov L.V. Comparison of 2 and 3 generations of thrombolytic drugs in patients with acute coronary syndrome with st segment elevation and ticagrelor administration no later than 3 hours after the end of fibrinolysis by frequency and severity of bleeding. Bulletin of Pirogov National Medical & Surgical Center. 2020;3-2(15):20-23. (In Russ.) https://doi.org/10.25881/BPNMSC.2020.15.42.004